Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea

Simon, Douglas; Cello, John P.; Valenzuela, Jorge; Levy, Richard A.; Dickerson, G.; Goodgame, Richard; Brown, Michael L.; Lyche, Kip; Fessel, W. J.; Grendell, James H.; Wilcox, C. Mel; Afdhal, Nezam H.; Fogel, Ronald; Reeves-Darby, Vonda G.; Stern, John J.; Smith, Owen J.; Graziano, Frank M.; Pleakow, Douglas; Flanigan, Timothy P.; Schubert, Timothy T.; Loveless, Mark O.; Eron, Larry; Basuk, Paul; Bonacini, Maurizio; Orenstein, Jan M.

doi:10.1016/0016-5085(95)90137-x

Cited by 65 publications

(39 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…186 The drug is given subcutaneously in doses of 50±100 lg t.d.s. Side-effects include decreased biliary motility (gallstones), diabetes and steatorrhea, the latter of which may potentially exacerbate diarrhoea.…”

Section: Idiopathic Oesophageal Ulcermentioning

confidence: 99%

The therapy of gastrointestinal infections associated with the acquired immunodeficiency syndrome

Wilcox

Mönkemüller

1997

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Although there have been dramatic strides in the therapy of human immunodeficiency virus infection over the last few years, the number of infected people world‐wide is tremendous and, at least in developing countries, continues to expand. Complications which involve the gastrointestinal tract are common in these patients, because the gut is a major site for involvement by opportunistic infections and neoplasms in patients with the acquired immunodeficiency syndrome. It is important to recognize the clinical spectrum of gastrointestinal diseases, as well as the appropriate and most cost‐effective diagnostic strategies, as therapies for a number of these disorders are both widely available and highly effective. This review summarizes the major gastrointestinal infections which are seen in patients with the acquired immunodeficiency syndrome, and their treatment.

show abstract

Section: Idiopathic Oesophageal Ulcermentioning

confidence: 99%

The therapy of gastrointestinal infections associated with the acquired immunodeficiency syndrome

Wilcox

Mönkemüller

1997

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…This study was followed by an open-label, dose-escalation phase with high doses of octreotide should be investigated [11]. starting doses of 300 g/day weekly increasing in 100-g steps up to a maximum dose of 1,500 g/day [10]. The response rate to octreotide was 48% as compared to 39%…”

mentioning

confidence: 99%

“…It may constitute a severe problem conhad a significant effect on both stool volume and frequency resulting in a 39% lower stool frequency and 42% tributing to diminished patient compliance, prolonged hospitalization and may even become live-threatening. lower stool volume at a dose of 1,500 g/day [10]. This study was criticized for the lack of a control of the pa-Symptomatic treatment with drugs like loperamide and diphenoxylate often fail and peroral medication may be tients' compliance, the heterogeneity in the study population and the lack of a standardized patients' diet [11].…”

mentioning

confidence: 99%

“…In future trials more homogenous patient populations should be evaluated ter, double-blind, placebo-controlled study in 129 patients, the effect of octreotide was evaluated during a 21-prominently including patients with secretory diarrhea with high stool outputs. The diet of the patients should day treatment schedule [10]. The trial included an initial double-blind, placebo-controlled study with an octreotide be standardized and the patient's compliance assured.…”

mentioning

confidence: 99%

“…However, none of the published trials has an ideal study design to exclude a possible beneficial performed evaluating the therapeutic effect of octreotide in AIDS-associated diarrhea [8][9][10]. In a large multicen-role of octreotide in this condition.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Octreotide in the Treatment of Refractory Diarrhea

Fried

1999

Digestion

View full text Add to dashboard Cite

Refractory chronic diarrhea that does not respond to specific antimicrobial therapy or standard unspecific medication may present a challening and serious clinical problem. Octreotide is a candidate drug for the treatment of these patients as it inhibits gastrointestinal motility, pancreatic secretion and inhibits intestinal absorption. Only few mostly uncontrolled studies in small patient groups were published evaluating the efficacy of octreotide in the treatment of patients with chemotherapy-induced diarrhea, short-bowel syndrome, AIDS-associated diarrhea and other conditions with chronic diarrhea not responding to standard treatment. Most of these studies are not conclusive as they yielded either negative or controversial results. Octreotide may be tried in the treatment of refractory diarrhea, in particular AIDS-associated diarrhea if patients do not respond to conventional treatment strategies. Well-designed controlled trials in large patient groups are needed in order to define the place of octreotide in the treatment of patients with refractory diarrhea.

show abstract

Diarrhea

Bruyn¹,

Bouckenooghe²

2004

Evidence‐based Infectious Diseases

View full text Add to dashboard Cite

Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea

Cited by 65 publications

References 9 publications

The therapy of gastrointestinal infections associated with the acquired immunodeficiency syndrome

The therapy of gastrointestinal infections associated with the acquired immunodeficiency syndrome

Octreotide in the Treatment of Refractory Diarrhea

Diarrhea

Contact Info

Product

Resources

About